An immunotherapy drug called Jemperli, also known as dostarlimab, has been found to be 100 percent successful in eliminating bowel cancer, potentially sparing patients from surgery and chemotherapy. The drug, developed by British pharmaceutical giant GSK, showed unprecedented results in a clinical trial, with all 42 patients treated showing no trace of the disease remaining.
Jemperli is already approved by the UK’s National Health Service (NHS) for women with certain types of advanced or recurrent womb cancer. Immunotherapy drugs like Jemperli use the body’s own immune system to target cancer cells, offering a promising alternative to traditional treatments like surgery, chemotherapy, and radiotherapy.
The cost of Jemperli is around £6,000 per dose in the UK and $12,000 in the United States. The NHS has made agreements with pharmaceutical companies to make immunotherapies like Jemperli available to patients.
The trial focused on patients with locally advanced mismatch repair deficient (dMMR) rectal cancer, a rare form of bowel cancer. The results of the trial were presented at the American Society of Clinical Oncology (ASCO) conference, where researchers and industry representatives gathered to discuss the findings.
The success of Jemperli in eliminating tumours without the need for chemotherapy and surgery has been hailed as a breakthrough in cancer treatment. GSK is continuing trials to further evaluate the drug’s potential.
Colorectal cancer rates have been on the rise, particularly among younger people, due to factors like obesity, poor diets, and physical inactivity. Bowel cancer is a significant cause of cancer-related deaths in the UK, but experts believe that over half of cases could be prevented through healthier lifestyle choices.
Please rephrase this sentence.
Source link
